Envestnet Asset Management
ADAP

Envestnet Asset Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Envestnet Asset Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-42,115
Closed -$336K – 3268
2020
Q3 		$336K Buy
+42,115
New +$369K ﹤0.01% 2684

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Envestnet Asset Management's ADAP Position: Q4 2020 in Review

Envestnet Asset Management sold out of Adaptimmune Therapeutics (ADAP) in Q4 2020, closing a stake of 42,115 shares — an estimated $336K sold.

Envestnet Asset Management first reported a position in ADAP in Q3 2020 and held it in 1 quarter. The position peaked at $336K in Q3 2020. 87 funds tracked by Wall St. Rank hold ADAP as of Q4 2020.

  • Envestnet Asset Management reported no remaining Adaptimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Envestnet Asset Management sold 42,115 Adaptimmune Therapeutics shares in Q4 2020, an estimated $336K.
  • Envestnet Asset Management first reported a position in Adaptimmune Therapeutics in Q3 2020 and held it in 1 quarter.
  • Envestnet Asset Management's Adaptimmune Therapeutics position peaked at $336K in Q3 2020.
  • 87 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2020.

Based on Envestnet Asset Management's 13F filing for Q4 2020, filed 2 Feb 2021.